You are here

STRYKAGEN CORPORATION

Company Information
Address
1664 N VIRGINIA ST, ROSS HALL 106, MS 321
RENO, NV 89557-0001
United States


http://www.strykagen.com

Information

DUNS: 079173703

# of Employees: 3


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    Amount: $747,570.00

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding pr ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Galectin-1 Protein Therapy for Congenital Muscular Dystrophy

    Amount: $225,000.00

    Abstract Lamininrelated congenital muscular dystrophyLAMACMDalso known as Merosin Deficient Congenital Muscular DystrophyMDC Ais a fatal muscle wasting disease that affects patients from birthLAMACMD ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    Amount: $224,999.00

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    Amount: $225,000.00

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government